UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment of rabies

Author
Alfred DeMaria, Jr, MD
Section Editors
Martin S Hirsch, MD
Morven S Edwards, MD
Deputy Editor
Jennifer Mitty, MD, MPH

INTRODUCTION

The rabies virus is a single stranded RNA virus that is highly neurotropic, and infects animals and humans. Rabies is one of the oldest and most feared human diseases with the highest case fatality rate of any infectious disease [1]. The clinical illness is characterized by motor weakness, paresthesias, and acute, progressive encephalitis with coma and death [2].

Despite the development of the first rabies vaccine in 1885, the World Health Organization estimates that between 30,000 and 70,000 people die worldwide of rabies each year [3]. Most of these deaths occur in developing countries because of inadequate control of rabies in domesticated animals. In the United States, there has been an average of two to three fatal human cases per year since 1980, mainly related to bat-associated rabies viruses [4-7].

The management of the patient with rabies and the use of experimental therapies/protocols will be reviewed here. The epidemiology, clinical manifestations, diagnosis, and prevention of rabies are discussed elsewhere. (See "Clinical manifestations and diagnosis of rabies" and "Rabies immune globulin and vaccine" and "When to use rabies prophylaxis".)

APPROACH TO TREATMENT

There is no proven effective therapy for rabies. Thus, preventing human rabies infection through the use of either pre-exposure prophylaxis (for high-risk groups) or post-exposure prophylaxis remains the cornerstone of management [8,9]. (See "When to use rabies prophylaxis" and "Rabies immune globulin and vaccine".)

For patients with symptomatic rabies, treatment is mostly supportive. However, in rare situations, the use of an aggressive treatment protocol may provide some benefit. (See 'Milwaukee protocol' below.)

          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri Aug 26 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Warner CK, Zaki SR, Shieh WJ, et al. Laboratory investigation of human deaths from vampire bat rabies in Peru. Am J Trop Med Hyg 1999; 60:502.
  2. Jackson AC, Warrell MJ, Rupprecht CE, et al. Management of rabies in humans. Clin Infect Dis 2003; 36:60.
  3. Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005; 83:360.
  4. Noah DL, Drenzek CL, Smith JS, et al. Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med 1998; 128:922.
  5. Krebs JW, Noll HR, Rupprecht CE, Childs JE. Rabies surveillance in the United States during 2001. J Am Vet Med Assoc 2002; 221:1690.
  6. Krebs JW, Mandel EJ, Swerdlow DL, Rupprecht CE. Rabies surveillance in the United States during 2004. J Am Vet Med Assoc 2005; 227:1912.
  7. Monroe BP, Yager P, Blanton J, et al. Rabies surveillance in the United States during 2014. J Am Vet Med Assoc 2016; 248:777.
  8. World Health Organization. WHO expert consultation on rabies: second report http://apps.who.int/iris/bitstream/10665/85346/1/9789241209823_eng.pdf (Accessed on July 30, 2013).
  9. Franka R, Rupprecht CE. Treatment of rabies in the 21st century: curing the incurable? Future Microbiol 2011; 6:1135.
  10. Jackson AC. Rabies. Handb Clin Neurol 2014; 123:601.
  11. Hattwick MA, Weis TT, Stechschulte CJ, et al. Recovery from rabies. A case report. Ann Intern Med 1972; 76:931.
  12. Porras C, Barboza JJ, Fuenzalida E, et al. Recovery from rabies in man. Ann Intern Med 1976; 85:44.
  13. Alvarez L, Fajardo R, Lopez E, et al. Partial recovery from rabies in a nine-year-old boy. Pediatr Infect Dis J 1994; 13:1154.
  14. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5907a1.htm (Accessed on March 05, 2012).
  15. Enright JB, Franti CE, Frye FL, Behymer DE. The effects of corticosteroids on rabies in mice. Can J Microbiol 1970; 16:667.
  16. Rubin RH, Sullivan L, Summers R, et al. A case of human rabies in Kansas: epidemiologic, clinical, and laboratory considerations. J Infect Dis 1970; 122:318.
  17. Miller A, Morse HC 3rd, Winkelstein J, Nathanson N. The role of antibody in recovery from experimental rabies. I. Effect of depletion of B and T cells. J Immunol 1978; 121:321.
  18. Kitselman, CH. 1964. Recovery of a rat from experimentally induced rabies. J Amer Vet Med Assn 144:1113.
  19. Willoughby RE, Roy-Burman A, Martin KW, et al. Generalised cranial artery spasm in human rabies. Dev Biol (Basel) 2008; 131:367.
  20. O'Sullivan A, Willoughby RE, Mishchuk D, et al. Metabolomics of cerebrospinal fluid from humans treated for rabies. J Proteome Res 2013; 12:481.
  21. Jackson AC. Rabies virus infection: an update. J Neurovirol 2003; 9:253.
  22. Hemachudha T, Ugolini G, Wacharapluesadee S, et al. Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol 2013; 12:498.
  23. Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res 2013; 99:61.
  24. Jackson AC. Recovery from rabies: a call to arms. J Neurol Sci 2014; 339:5.
  25. Willoughby RE Jr, Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med 2005; 352:2508.
  26. Aramburo A, Willoughby RE, Bollen AW, et al. Failure of the Milwaukee protocol in a child with rabies. Clin Infect Dis 2011; 53:572.
  27. Lockhart BP, Tordo N, Tsiang H. Inhibition of rabies virus transcription in rat cortical neurons with the dissociative anesthetic ketamine. Antimicrob Agents Chemother 1992; 36:1750.
  28. Centers for Disease Control and Prevention (CDC). Recovery of a patient from clinical rabies--Wisconsin, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:1171.
  29. Jackson AC. Recovery from rabies. N Engl J Med 2005; 352:2549.
  30. Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53.
  31. Superti F, Seganti L, Panà A, Orsi N. Effect of amantadine on rhabdovirus infection. Drugs Exp Clin Res 1985; 11:69.
  32. Hu WT, Willoughby RE Jr, Dhonau H, Mack KJ. Long-term follow-up after treatment of rabies by induction of coma. N Engl J Med 2007; 357:945.
  33. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a1.htm?s_cid=mm6104a1_x.
  34. McDermid RC, Saxinger L, Lee B, et al. Human rabies encephalitis following bat exposure: failure of therapeutic coma. CMAJ 2008; 178:557.
  35. Centers for Disease Control and Prevention (CDC). Human rabies--Indiana and California, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:361.
  36. Centers for Disease Control and Prevention (CDC). Human rabies--Alberta, Canada, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:197.
  37. Maier T, Schwarting A, Mauer D, et al. Management and outcomes after multiple corneal and solid organ transplantations from a donor infected with rabies virus. Clin Infect Dis 2010; 50:1112.
  38. Hemachudha T, Sunsaneewitayakul B, Desudchit T, et al. Failure of therapeutic coma and ketamine for therapy of human rabies. J Neurovirol 2006; 12:407.
  39. Hunter M, Johnson N, Hedderwick S, et al. Immunovirological correlates in human rabies treated with therapeutic coma. J Med Virol 2010; 82:1255.
  40. van Thiel PP, de Bie RM, Eftimov F, et al. Fatal human rabies due to Duvenhage virus from a bat in Kenya: failure of treatment with coma-induction, ketamine, and antiviral drugs. PLoS Negl Trop Dis 2009; 3:e428.
  41. Wilde H, Hemachudha T, Jackson AC. Viewpoint: Management of human rabies. Trans R Soc Trop Med Hyg 2008; 102:979.
  42. Centers for Disease Control and Prevention (CDC). Imported human rabies in a U.S. Army soldier - New York, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:302.
  43. Bussereau F, Picard M, Blancou J, Sureau P. Treatment of rabies in mice and foxes with antiviral compounds. Acta Virol 1988; 32:33.
  44. Hilfenhaus J, Weinmann E, Majer M, et al. Administration of human interferon to rabies virus-infected monkeys after exposure. J Infect Dis 1977; 135:846.
  45. Warrell MJ, White NJ, Looareesuwan S, et al. Failure of interferon alfa and tribavirin in rabies encephalitis. BMJ 1989; 299:830.
  46. Merigan TC, Baer GM, Winkler WG, et al. Human leukocyte interferon administration to patients with symptomatic and suspected rabies. Ann Neurol 1984; 16:82.
  47. Yamada K, Noguchi K, Komeno T, et al. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis 2016; 213:1253.
  48. Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010; 59:1.
  49. Helmick CG, Tauxe RV, Vernon AA. Is there a risk to contacts of patients with rabies? Rev Infect Dis 1987; 9:511.
  50. WHO Expert Consultation on rabies. World Health Organ Tech Rep Ser 2005; 931:1.
  51. Wallace RM, Stanek D, Griese S, et al. A large-scale, rapid public health response to rabies in an organ recipient and the previously undiagnosed organ donor. Zoonoses Public Health 2014; 61:560.
  52. Kan VL, Joyce P, Benator D, et al. Risk assessment for healthcare workers after a sentinel case of rabies and review of the literature. Clin Infect Dis 2015; 60:341.